Drugs like Ozempic and Wegovy could raise the risk of a rare form of vision loss, but we are still trying to unpick why ...

Patients using popular weight loss medications, such as Ozempic and Wegovy, are being urged to undergo eye examinations due to a potential risk of vision loss.

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

I had no idea this could happen. I wouldn’t have done it,” New Jersey-based former Mounjaro user James Norris, who is now visually impaired, told The Post ...

But that’s not hindering the search for a quick fix. Everywhere you look there is evidence of a voracious interest in ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

Patients on semaglutide (Ozempic, Wegovy) had a 32% increased relative risk of developing nonarteritic anterior ischemic optic neuropathy (NAION) compared to people not taking the drug ...

Opens in a new tab or window Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 diabetes. The risk was more modest than ...

It found that of nine patients, seven had nonarteritic anterior ischemic optic neuropathy, one had papillitis and another had patient is described with paracentral acute middle maculopathy.

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...